Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BMEA Biomea Fusion, Inc.

Market Closed 11-15 16:00:00 EST

6.53

-0.58

-8.16%

盘后6.53

+0.000.00%

17:39 EST

High7.11	Low6.48	Vol913.89K
Open7.02	D1 Closing7.11	Amplitude8.86%
Mkt Cap236.64M	Tradable Cap146.63M	Total Shares36.24M
T/O6.09M	T/O Rate4.07%	Tradable Shares22.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":6.53,"timestamp":1731704400000,"preClose":7.11,"halted":0,"volume":913891,"hourTrading":{"tag":"盘后","latestPrice":6.53,"preClose":6.53,"latestTime":"17:39 EST","volume":7167,"amount":46823.51,"timestamp":1731710365554},"delay":0,"floatShares":22455581,"shares":36238687,"eps":-4.002201,"marketStatus":"Market Closed","change":-0.58,"latestTime":"11-15 16:00:00 EST","open":7.02,"high":7.11,"low":6.48,"amount":6088070.964708,"amplitude":0.088608,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.002201,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":7,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":7.11,"preHourTrading":{"tag":"盘前","latestPrice":7.11,"preClose":7.11,"latestTime":"08:20 EST","volume":48,"amount":341.28,"timestamp":1731676800026},"postHourTrading":{"tag":"盘后","latestPrice":6.53,"preClose":6.53,"latestTime":"17:39 EST","volume":7167,"amount":46823.51,"timestamp":1731710365554},"volumeRatio":1.4020827551753292,"impliedVol":2.3078,"impliedVolPercentile":0.9643},"requestUrl":"/m/hq/s/BMEA/wiki","defaultTab":"wiki","newsList":[{"id":"2483707471","title":"We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483707471","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483707471?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:29","pubTimestamp":1731493767,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So, the natural question for Biomea Fusion  shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.Since it has a market capitalisation of US$291m, Biomea Fusion's US$113m in cash burn equates to about 39% of its market value. That's not insignificant, and if the company had to sell enough shar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-little-worried-biomea-fusions-102927112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","BK4539","MNQmain","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","BK4139","NQmain","BK4588","LU2095319765.USD","IE00B64PRP62.GBP","PSQ","SQQQ","LU2210149790.SGD","BK4585","BK4112","IE00BGHQF748.EUR","QLD","BMEA","QID",".IXIC"],"gpt_icon":1},{"id":"2480849852","title":"Press Release: Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2480849852","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480849852?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:05","pubTimestamp":1730491500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov. 01, 2024  -- Biomea Fusion, Inc.  , a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on November 1, 2024, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 6,500 shares of the Company's common stock. The shares underlying the employee's stock options will vest 1/16 on a quarterly basis over four years, subject to the employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan .The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635 and was granted pursuant to the terms of the Plan. The Plan","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BMEA","NQmain",".IXIC","BK4099","LU2095319765.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4555","BK4139","BK4585","03160","BK4539","BK4112","LU2210149790.SGD","TM","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588"],"gpt_icon":1},{"id":"2480057041","title":"Biomea Fusion Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2480057041","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480057041?lang=en_us&edition=fundamental","pubTime":"2024-11-01 02:34","pubTimestamp":1730399640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 14:34 ET (18:34 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2479830750","title":"Oppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479830750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479830750?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:09","pubTimestamp":1730376540,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler maintained a Buy rating on Biomea Fusion (BMEA – Research Report) today and set a price target of $60.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-biomea-fusion-bmea?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-biomea-fusion-bmea?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA","OPY"],"gpt_icon":0},{"id":"2479042297","title":"Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2479042297","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479042297?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:12","pubTimestamp":1730373120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 07:12 ET (11:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2479096767","title":"Analysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), GE Healthcare Technologies Inc (GEHC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479096767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479096767?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:50","pubTimestamp":1730371853,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biomea Fusion (BMEA – Research Report), GE Healthcar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biomea-fusion-bmea-ge-healthcare-technologies-inc-gehc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biomea-fusion-bmea-ge-healthcare-technologies-inc-gehc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0868494617.USD","BK4588","LU1551013342.USD","LU2264538146.SGD","LU0820561909.HKD","LU1064131342.USD","LU2756315664.SGD","BMEA","LU1988902786.USD","BK4585","LU0149725797.USD","LU2756315318.SGD","BK4187","LU1280957306.USD","LU1093756168.USD","GEHC","LU1261432733.SGD","LU1551013425.SGD","BK4501","LU0354030511.USD","BK4539","LU1366333091.USD","BK4139","LU0157215616.USD","LU0640476718.USD","LU0943347566.SGD","LU0124676726.USD","BK4566","LU0689626769.HKD","LU0820562030.AUD","BK4082","GE","LU1093756325.SGD","LU0354030438.USD","LU0820561818.USD","BK4206","LU0689472784.USD"],"gpt_icon":0},{"id":"2479775251","title":"Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of Glp-1-Based Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2479775251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479775251?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:00","pubTimestamp":1730318457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61J8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BMEA","BK4139","BK4585"],"gpt_icon":0},{"id":"2479512752","title":"Biomea Fusion Inc - Introduces Bmf-650, a Next-Generation, Oral Small-Molecule Glp-1 Receptor Agonist Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2479512752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479512752?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:00","pubTimestamp":1730318457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61J8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BMEA","BK4539"],"gpt_icon":0},{"id":"2479375233","title":"Biomea Fusion Inc - Phase Ii Study (Covalent-211), Combining Icovamenib With a Glp-1-Based Therapy, Planned to Begin in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2479375233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479375233?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:00","pubTimestamp":1730318457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4585","BK4139","BMEA"],"gpt_icon":0},{"id":"2479475208","title":"Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2479475208","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479475208?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:00","pubTimestamp":1730318400,"startTime":"0","endTime":"0","summary":"Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to incre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/30/2972029/0/en/Biomea-Fusion-Presents-Preclinical-Data-Showing-Icovamenib-BMF-219-Enhanced-Effectiveness-of-GLP-1-Based-Therapies-and-Introduces-BMF-650-a-Next-Generation-Oral-Small-Molecule-GLP-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","BK4590","BMEA","BK4539","GLP","BK4585","BK4139"],"gpt_icon":0},{"id":"2479844357","title":"Biomea Fusion Is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2479844357","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479844357?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:47","pubTimestamp":1730299620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 10:47 ET (14:47 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BMEA","BK4539"],"gpt_icon":0},{"id":"2479070542","title":"Biomea Fusion Is Maintained at Buy by EF Hutton","url":"https://stock-news.laohu8.com/highlight/detail?id=2479070542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479070542?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:08","pubTimestamp":1730293680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 09:08 ET (13:08 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2479278590","title":"Biomea Fusion Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2479278590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479278590?lang=en_us&edition=fundamental","pubTime":"2024-10-30 17:28","pubTimestamp":1730280490,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc ( ($BMEA) ) has realeased its Q3 earnings. Here is a breakdown of the information Biomea Fusion Inc presented to its investors. B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA","BK4585","BK4539","BK4139"],"gpt_icon":0},{"id":"2479975897","title":"U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs","url":"https://stock-news.laohu8.com/highlight/detail?id=2479975897","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479975897?lang=en_us&edition=fundamental","pubTime":"2024-10-30 14:34","pubTimestamp":1730270073,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, CrocsOct 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilon Health","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nL4N3M60P2:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","AGL","BY","CAKE","V","CALX","LU","BRO","SKY","TXG","ACA","APP","ATGE","AXTA","AMZN","CROX","AWI","BMRN","CHPT","IE00B64QTZ34.USD","CZR","AJG","IE00BZ1G4Q59.USD","ALSN","CBNA","ATI","AMT","AESI","ALHC","ALNY","CWH","LU0889565833.HKD","GOOGL","BWFG","LU0052756011.USD","BP","ABG","CNC","GOOG","BK4173","BYD","BMEA","LU1803068979.SGD","ADC","CAC","ATRC","IE00B3PB1722.GBP","AMD","ANET","CECO"],"gpt_icon":1},{"id":"2479919722","title":"Biomea Fusion GAAP EPS of -$0.91 beats by $0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2479919722","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479919722?lang=en_us&edition=fundamental","pubTime":"2024-10-30 05:01","pubTimestamp":1730235674,"startTime":"0","endTime":"0","summary":"Biomea Fusion press release  (NASDAQ:BMEA): Q3  GAAP EPS of -$0.91  beats by $0.04.\nCash, Equivalents, and Restricted Cash: As of September 30, 2024, the Company had cash, cash equivalents and restricted cash of $88.3 million, compared to $177.2 million as of December 31, 2023.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4221097-biomea-fusion-gaap-eps-of-0_91-beats-0_04","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BMEA"],"gpt_icon":0},{"id":"2479250510","title":"Biomea Fusion Q3 EPS $(0.91) Beats $(1.00) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2479250510","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479250510?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:56","pubTimestamp":1730235411,"startTime":"0","endTime":"0","summary":"Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.00) by 9 percent. This is a 13.75 percent decrease over losses of $(0.80) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41612506/biomea-fusion-q3-eps-0-91-beats-1-00-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Biomea Fusion Q3 EPS $(0.91) Beats $(1.00) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2479500872","title":"Biomea Fusion reports Q3 EPS (91c), consensus (95c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479500872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479500872?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:50","pubTimestamp":1730235022,"startTime":"0","endTime":"0","summary":"As of September 30 the Company had cash, cash equivalents and restricted cash of $88.3M, compared to $177.2M as of December 31, 2023. “Our Q3 was a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-reports-q3-eps-91c-consensus-95c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-reports-q3-eps-91c-consensus-95c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0},{"id":"2479925750","title":"Biomea Fusion Q3 Operating Income USD -34.039 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2479925750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479925750?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:46","pubTimestamp":1730234768,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nPLXA1D79F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4539","BK4585","BK4139"],"gpt_icon":0},{"id":"2479257449","title":"Press Release: Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2479257449","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479257449?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:46","pubTimestamp":1730234760,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  lifted Clinical Hold on. -- COVALENT-111 Phase 2b 26-week topline data of the dose expansion cohorts. -- On track to announce our third clinical candidate, BMF-650, for the. treatment of diabetes and obesity -- a next-generation, oral. small-molecule GLP-1 receptor agonist  - and preclinical data. combining icovamenib  with a GLP-1 RA-based therapy on October. -- Announced formation of Biomea's Global Scientific Advisory Board with 22. REDWOOD CITY, Calif., Oct. 29, 2024  -- Biomea Fusion, Inc.  , a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate highlights.-- Announced that the FDA lifted the clinical hold on the ongoing Phase 1/2. clinical trials in type 2 and type 1 diabetes (COVALENT-111 and. -- Announced the formation of our glo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","03160","BK4181","BK4539","BMEA","INN","BK4585","BK4139","BK4218","BK4099","TM","BK4588"],"gpt_icon":0},{"id":"2479453821","title":"Biomea Fusion options imply 6.1% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2479453821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479453821?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:20","pubTimestamp":1730139608,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-options-imply-6-1-move-in-share-price-post-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-options-imply-6-1-move-in-share-price-post-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":-0.2017},{"period":"1month","weight":-0.4327},{"period":"3month","weight":0.1298},{"period":"6month","weight":-0.4665},{"period":"1year","weight":-0.3001},{"period":"ytd","weight":-0.5503}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.111851},{"month":2,"riseRate":0.333333,"avgChangeRate":0.070637},{"month":3,"riseRate":0.333333,"avgChangeRate":0.321728},{"month":4,"riseRate":0,"avgChangeRate":-0.21954},{"month":5,"riseRate":0.75,"avgChangeRate":0.245778},{"month":6,"riseRate":0.25,"avgChangeRate":0.039512},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004694},{"month":8,"riseRate":0.75,"avgChangeRate":0.054176},{"month":9,"riseRate":0.25,"avgChangeRate":-0.024488},{"month":10,"riseRate":0.25,"avgChangeRate":-0.076889},{"month":11,"riseRate":0.5,"avgChangeRate":-0.012766},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.082267}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction